AbbVie Inc.
ABBVPharma & biotechabbvie.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Nov 3, 2026
Next reportFebruary 2, 2027after close · forecast 3.958 $/share
Revenue
$17.40B
▲ +10.3% vs prior year YoY
Net income
$4.22B
▲ +2167.7% vs prior year YoY
EPS
2.37$
▲ +2270.0% vs prior year YoY
Net margin
24.2%
▲ +23.1 pp vs prior year YoY
Revenue▲ +10.3%
Margins (% of revenue)GrossOperatingNet
Net income▲ +2167.7%
EPS▲ +2270.0%
Financial statements
View 10-Q filed November 3, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $15.10B | $13.34B | $15.42B | $15.78B | $16.62B | $15.00B | $16.99B | $17.40B | ▲ +10.3% |
| Gross profit | $10.71B | $9.34B | $11.08B | $10.47B | $12.07B | $10.78B | $12.70B | $13.12B | ▲ +25.3% |
| Operating income | −$1.49B | $3.73B | $4.89B | $1.90B | $4.54B | $3.99B | $6.43B | $6.27B | ▲ +229.1% |
| Net income | −$22.00M | $1.29B | $938.00M | $186.00M | $1.82B | $695.00M | $3.61B | $4.22B | ▲ +2167.7% |
| R&Dnever filed | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | 0.72 $ | 0.52 $ | 0.10 $ | — | 0.39 $ | 2.03 $ | 2.37 $ | ▲ +2270.0% |
| Margins (% of revenue) | |||||||||
| Gross | 70.9 % | 70.0 % | 71.8 % | 66.4 % | 72.6 % | 71.9 % | 74.7 % | 75.4 % | ▲ +9.0 pt |
| Operating | -9.9 % | 28.0 % | 31.7 % | 12.1 % | 27.3 % | 26.6 % | 37.9 % | 36.0 % | ▲ +23.9 pt |
| Net | -0.1 % | 9.6 % | 6.1 % | 1.2 % | 10.9 % | 4.6 % | 21.3 % | 24.2 % | ▲ +23.1 pt |
| Balance sheet | |||||||||
| Assets | $135.16B | $136.16B | $137.18B | $133.90B | $133.96B | $136.46B | $135.12B | $147.68B | ▲ +10.3% |
| Liabilities | $131.80B | $134.70B | $137.32B | $136.50B | $137.19B | $143.07B | $141.00B | $152.22B | ▲ +11.5% |
| Equity | $3.36B | $1.46B | −$138.00M | −$2.60B | −$3.23B | −$6.61B | −$5.89B | −$4.54B | ▼ -74.6% |
| Cash | $5.52B | $5.17B | $6.47B | $5.63B | $5.23B | $9.39B | $6.57B | $10.77B | ▲ +91.4% |
| Capital | |||||||||
| Shares outstanding | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | ▲ +0.0% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.